Name: U-Blot® Research Grade Vobramitamab
SKU: WA3793
Price: 9999 USD
Availability: InStock

U-Blot® Research Grade Vobramitamab

Ucallm.jpg

$9,999.00

Size

100ug

50ug

Clear

SKU: WA3793-50

Enter the quantity you would like, or drag the panel to find the quantity and price that best for you

Bulk Quote Authorize OEM & ODM

Product details

Background：Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.

Specifications

Target	CD276
Reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
MW(Calculated)
MW(Observed)
Host Species	Humanized
Isotype	IgG1-kappa
Conjugate/Modification
Modification
Recommended Dilution Ratio
Composition	0.01M PBS, pH 7.4.
Purification Process	Protein A/G purified from cell culture supernatant.
Purity	>95% purity as determined by SDS-PAGE.
Storage Condition	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Concentration
Clonality	Monoclonal
Clone Number
Immunogen	Mammalian Cells
Gene Name
Protein Name
Alias	CD276, B7-H3, Costimulatory molecule, B7H3, 4Ig-B7-H3, B7 homolog 3, CD276 antigen
Species
Gene ID-1	Q5ZPR3
Uniprot
Species.1
Gene ID
Uniprot.1
Species.2
Gene ID.1
Uniprot.2
Organism-4
Gene ID-4
SwissProt-4
Description	Background：Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.<br>
Cellular Localization
Tissue Expression
Signaling_pathway
Research Areas
Function